Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.

Purpose: No previous prospective trials have been reported with sorafenib in patients with sunitinib-refractory metastatic renal cell cancer (MRCC). We conducted a multicenter study to determine the activity and tolerability of sorafenib as second-line therapy after sunitinib progression in MRCC.

Patients And Methods: Between January 2006 and September 2008, 52 patients were enrolled onto this single-arm phase II study.

Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients.

The objective of this study was to evaluate the use of paclitaxel in patients with advanced squamous cell penile cancer previously treated with neoadjuvant cisplatin-based chemotherapy. This was a single-arm, phase II, multicenter study. Patients were treated with 175 mg/m paclitaxel at a 3-week interval, until disease progression or irreversible toxicity.